Author

Vincent J Sartori

Van Andel InstituteORCID 0000-0001-6591-029XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alexander C. MonovichiD· 1 shared Althea N. Waldhart· 1 shared Amy JohnsoniD· 1 shared Ashley K. WisemaniD· 1 shared Bradley M. DicksoniD· 1 shared Cameron J. Lee· 1 shared Colton Dysart· 1 shared Connor G Burke· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander C. MonovichORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular BiologybioRxivPreprintSep 26, 2026

A feed-forward UHRF1 read-write mechanism supports H3 multi- mono-ubiquitination and DNA methylation maintenance at CpG-sparse regions

Joel A. Hrit, Rochelle L. Tiedemann, Vincent J Sartori…·Scott B. Rothbart

This study identifies a feed-forward mechanism where UHRF1 reads and writes H3 mono-ubiquitination to maintain DNA methylation at CpG-sparse regions.

DOI 10.64898/2026.09.25.754493

𝕏 PostBluesky

Cancer BiologyBlood NeoplasiaPeer-reviewedSep 1, 2026

EZH2-driven immune evasion at disease presentation defines atargetable high-risk subset of acute leukemia exemplified byt(16;21) FUS::ERG AML

Nathaniel J. Buteyn, Samantha J LaMantia, Connor G Burke…·Timothy Junius Triche

This paper identifies an EZH2-driven immune evasion phenotype in FUS::ERG AML that is reversible with tazemetostat, offering a potential targeted therapy for high-risk acute leukemia.

6 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature MetabolismPeer-reviewedSep 8, 2025

An alternative route for β-hydroxybutyrate metabolism supports fatty acid synthesis in cancer cells

Faith C Kaluba, Thomas J. Rogers, Yu‐Jin Jeong…·Evan C. Lien

This study identifies a non-canonical metabolic pathway in cancer cells that uses β-hydroxybutyrate for fatty acid synthesis, supporting tumor growth under lipid-limited conditions.

17 citationstop 2%

humanmetabolomics

𝕏 PostBluesky